WallStreetZenWallStreetZen

NASDAQ: ADMA
Adma Biologics Inc Stock

$3.53-0.05 (-1.4%)
Updated Oct 2, 2023
ADMA Price
$3.53
Fair Value Price
$3.84
Market Cap
$793.92M
52 Week Low
$2.44
52 Week High
$4.65
P/E
-17.65x
P/B
5.41x
P/S
3.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$208.11M
Earnings
-$40.29M
Gross Margin
27.4%
Operating Margin
-7.96%
Profit Margin
-19.4%
Debt to Equity
1.34
Operating Cash Flow
-$41M
Beta
0.87
Next Earnings
Nov 7, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ADMA Overview

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ADMA ($3.53) is undervalued by 8.12% relative to our estimate of its Fair Value price of $3.84 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ADMA ($3.53) is not significantly undervalued (8.12%) relative to our estimate of its Fair Value price of $3.84 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ADMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADMA due diligence checks available for Premium users.

Be the first to know about important ADMA news, forecast changes, insider trades & much more!

ADMA News

Valuation

ADMA fair value

Fair Value of ADMA stock based on Discounted Cash Flow (DCF)
Price
$3.53
Fair Value
$3.84
Undervalued by
8.12%
ADMA ($3.53) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADMA ($3.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ADMA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-17.65x
Industry
14.19x
Market
12.38x

ADMA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.41x
Industry
5.05x
ADMA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ADMA's financial health

Profit margin

Revenue
$60.1M
Net Income
-$6.4M
Profit Margin
-10.6%
ADMA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADMA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$343.0M
Liabilities
$196.3M
Debt to equity
1.34
ADMA's short-term assets ($266.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADMA's short-term assets ($266.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADMA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ADMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.1M
Investing
-$872.6k
Financing
$240.1k
ADMA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ADMA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ADMA$793.92M-1.40%-17.65x5.41x
VALN$787.54M-2.07%59.37x3.88x
ICPT$777.16M+0.32%3.27x11.51x
COGT$816.19M-2.05%-4.36x2.34x
NAMS$819.67M-8.97%-1.48x1.73x

Adma Biologics Stock FAQ

What is Adma Biologics's quote symbol?

(NASDAQ: ADMA) Adma Biologics trades on the NASDAQ under the ticker symbol ADMA. Adma Biologics stock quotes can also be displayed as NASDAQ: ADMA.

If you're new to stock investing, here's how to buy Adma Biologics stock.

What is the 52 week high and low for Adma Biologics (NASDAQ: ADMA)?

(NASDAQ: ADMA) Adma Biologics's 52-week high was $4.65, and its 52-week low was $2.44. It is currently -24.09% from its 52-week high and 44.67% from its 52-week low.

How much is Adma Biologics stock worth today?

(NASDAQ: ADMA) Adma Biologics currently has 224,906,426 outstanding shares. With Adma Biologics stock trading at $3.53 per share, the total value of Adma Biologics stock (market capitalization) is $793.92M.

Adma Biologics stock was originally listed at a price of $8.55 in Oct 17, 2013. If you had invested in Adma Biologics stock at $8.55, your return over the last 9 years would have been -58.71%, for an annualized return of -9.36% (not including any dividends or dividend reinvestments).

How much is Adma Biologics's stock price per share?

(NASDAQ: ADMA) Adma Biologics stock price per share is $3.53 today (as of Oct 2, 2023).

What is Adma Biologics's Market Cap?

(NASDAQ: ADMA) Adma Biologics's market cap is $793.92M, as of Oct 3, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Adma Biologics's market cap is calculated by multiplying ADMA's current stock price of $3.53 by ADMA's total outstanding shares of 224,906,426.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.